Celgene & BMS v. MSN Laboratories: Consent Judgment in Cytidine Analog Patent Dispute
Celgene Corporation and Bristol-Myers Squibb filed suit in Delaware against MSN Laboratories over two patents protecting oral formulations of cytidine analogs — a key drug class in oncology. The parties reached a consent judgment and order of dismissal in just 247 days, suggesting a negotiated resolution that likely defines MSN’s path to market entry.
Swift consent judgment in Delaware pharmaceutical patent dispute
Celgene Corp., Bristol-Myers Squibb Company, and Celgene International SARL filed this infringement action on 27 June 2023 in the Delaware District Court before Chief Judge Jennifer L. Hall. The defendants — MSN Laboratories Private Limited and MSN Pharmaceuticals, Inc. — are generic drug manufacturers whose proposed oral cytidine analog product triggered the suit. The asserted patents, US11571436B2 and US8846628B2, cover oral formulations of cytidine analogs and methods of use, a drug class with significant oncology applications.
The case closed on 29 February 2024 via a Consent Judgment and Order of Dismissal — a mechanism under which both parties agree to a court-entered judgment, typically embedding negotiated terms on market entry, licensing, or future conduct. Unlike a standard voluntary dismissal, a consent judgment is enforceable by the court and is binding on the defendant. The 247-day timeline from filing to resolution is notably short for pharmaceutical patent litigation, which frequently extends two to four years through trial.
The speed of resolution suggests the parties likely reached a commercial accommodation — potentially a market entry date or sublicense for MSN — rather than litigating validity or infringement to judgment. The specific terms of any underlying agreement are not disclosed in the public record, which is typical for consent judgments in ANDA-related pharmaceutical disputes. What remains unknown is whether MSN’s market entry rights are exclusive, the date on which any such entry is permitted, and whether royalties were agreed.
Filing to settlement in 247 days
247 days — faster than the median ANDA patent trial in Delaware District Court
What the consent judgment means for Celgene, BMS, and MSN
Consent judgment: agreed order, not litigated outcome
A consent judgment is a court-entered order reflecting terms agreed between both parties. Unlike a dismissal, it carries the full enforcement weight of a court ruling. Neither party admitted wrongdoing, but MSN is bound by the judgment’s terms. This mechanism is commonly used in pharmaceutical patent disputes to fix a market-entry date or licensing condition without disclosing deal terms publicly.
Court-enforceable agreed orderMSN’s generic launch: deferred, licensed, or barred?
Consent judgments in Hatch-Waxman-adjacent disputes typically incorporate an agreed market entry date — often tied to patent expiry or a negotiated launch window. The public record does not disclose MSN’s launch rights. However, the structured resolution suggests MSN secured some forward path rather than conceding infringement outright. Stakeholders tracking MSN’s cytidine analog product should monitor FDA approval status and any subsequent market activity.
Launch terms undisclosedTwo patents resolved — portfolio coverage remains active
The consent judgment covers US11571436B2 (application filed 2021, granted 2023) and US8846628B2 (application filed 2009, granted 2014). Both patents remain in force against third parties. The resolution in this case does not affect Celgene/BMS’s ability to assert either patent against other generic entrants. Competitors developing oral cytidine analog formulations should treat this outcome as confirmation that the patent holder actively enforces these assets.
Patents remain enforceable vs. othersDelaware: preferred venue for pharma patent enforcement
Delaware District Court is the dominant venue for pharmaceutical patent litigation in the United States, frequently selected by innovator companies for its experienced judiciary and predictable scheduling. Chief Judge Jennifer L. Hall presided. The case’s quick resolution means no substantive rulings on claim construction, validity, or infringement were issued — limiting the precedential value of this filing for third parties.
No claim construction ruling issuedFull party and counsel information
| Role | Name | Typ | Detail |
|---|---|---|---|
| Kläger | Celgene, Corp. | Unternehmen | Pharmaceutical IP holders — Celgene/BMS — asserting US11571436B2 and US8846628B2Search in Eureka ↗ |
| Beklagter | MSN Laboratories Private Limited | Unternehmen | MSN Laboratories Private Limited — Indian generic drug manufacturer seeking US market entrySearch in Eureka ↗ |
| Plaintiff counsel | Amy K. Wigmore | Attorney | Counsel for Celgene, Corp.Search in Eureka ↗ |
| Plaintiff counsel | Andrew J. Danford | Attorney | Counsel for Celgene, Corp.Search in Eureka ↗ |
| Plaintiff counsel | Brian E. Farnan | Attorney | Counsel for Celgene, Corp.Search in Eureka ↗ |
| Plaintiff counsel | David Mlaver | Attorney | Counsel for Celgene, Corp.Search in Eureka ↗ |
| Plaintiff counsel | Gerard A. Salvatore | Attorney | Counsel for Celgene, Corp.Search in Eureka ↗ |
| Plaintiff counsel | Heather M. Petruzzi | Attorney | Counsel for Celgene, Corp.Search in Eureka ↗ |
| Plaintiff counsel | Joseph J. Farnan , Jr. | Attorney | Counsel for Celgene, Corp.Search in Eureka ↗ |
| Plaintiff counsel | Li-tsung A. Chen | Attorney | Counsel for Celgene, Corp.Search in Eureka ↗ |
| Plaintiff counsel | Michael J. Farnan | Attorney | Counsel for Celgene, Corp.Search in Eureka ↗ |
| Plaintiff counsel | Nora Q.E. Passamaneck | Attorney | Counsel for Celgene, Corp.Search in Eureka ↗ |
| Defendant counsel | Stamatios Stamoulis | Attorney | Counsel for MSN Laboratories Private LimitedSearch in Eureka ↗ |
| Presiding judge | Judge Jennifer L. Hall | Oberster Richter | Delaware District Court — Chief JudgeSearch in Eureka ↗ |
Stipulation of dismissal — official text
The ‘Consent Judgment and Order of Dismissal’ is a negotiated, court-entered resolution rather than a finding on the merits. For Celgene and BMS, it preserves the validity and enforceability of both asserted patents against all other parties. For MSN, it closes the litigation without a public admission of infringement, though the binding order constrains MSN’s conduct as agreed. The absence of publicly disclosed terms is standard practice in pharmaceutical patent settlements of this type.
US11571436B2 & US8846628B2 — Oral Cytidine Analog Formulations
US11571436B2 stems from application US17/533033 and was granted in 2023, covering oral formulations of cytidine analogs and their therapeutic methods of use — a drug class relevant to haematological oncology. US8846628B2 derives from application US12/466213, filed in 2009 and granted in 2014, representing an earlier layer of the same formulation technology. Together, these patents form a stacked exclusivity position over oral cytidine analog delivery, protecting not just the compound but the specific formulation approach enabling oral bioavailability.
For the pharmaceutical sector, cytidine analogs with viable oral formulations represent a significant commercial advance over intravenous administration — improving patient adherence and expanding market reach. Celgene and BMS’s decision to litigate immediately on receiving MSN’s challenge confirms these patents are treated as core revenue-protection assets. The 2023-granted US11571436B2 is particularly strategically significant: its recency suggests BMS has actively continued to build out its formulation patent estate, potentially extending exclusivity beyond the expiry of the 2014-granted patent.
Should you run an FTO against US11571436B2 and US8846628B2?
Any company developing, manufacturing, or planning to commercialise an oral formulation of a cytidine analog in the United States should treat these two patents as high-priority FTO targets. The BMS/Celgene enforcement record — including this Delaware suit against MSN — demonstrates a consistent willingness to litigate promptly. Product teams working on oral oncology formulations, particularly those in the azacitidine or decitabine class, should assess claim scope before committing to clinical or regulatory investment.
PatSnap Eureka’s FTO Search Agent can map your formulation’s technical features against the independent and dependent claims of both US11571436B2 and US8846628B2, flagging overlap risk at the claim element level. Eureka’s claim monitoring tool will also alert your team if BMS files continuation applications extending coverage — critical given the active prosecution history suggested by the 2023 grant date of US11571436B2. Set up a portfolio watch on Celgene and Bristol-Myers Squibb to track new filings in this technology space.
Run a freedom-to-operate analysis on US11571436B2 to assess your product’s exposure
Run FTO in Eureka →Similar pharmaceutical oral formulation patent disputes in Delaware
PatSnap Eureka tracks related litigation across truck body equipment, vehicle accessories, and comparable infringement actions in the Georgia district system.
What this case signals for the oncology oral formulation IP landscape
A fast consent judgment here confirms active enforcement posture — and sets a market access template that competitors in this drug class should study.
Celgene/BMS is actively enforcing oral cytidine analog patents
This filing demonstrates that BMS — through its Celgene subsidiary — treats US11571436B2 and US8846628B2 as commercially critical assets worth immediate litigation. Any generic manufacturer filing an ANDA or equivalent for an oral cytidine analog product should anticipate receiving a similar suit within weeks of certification notice.
Consent judgments are the dominant exit for early pharma patent disputes
Resolution in under 250 days without a trial is consistent with a negotiated market-entry agreement. For in-house teams tracking competitor generics, this signals that MSN likely has a defined launch window — monitoring FDA’s Orange Book for MSN’s product listing will reveal whether an authorised entry date has been lodged.
Celgene v MSN — key questions answered
Celgene and Bristol-Myers Squibb asserted US11571436B2 and US8846628B2 against MSN Laboratories. Both patents cover oral formulations of cytidine analogs and methods of use, protecting different layers of the same formulation technology with grant dates of 2014 and 2023 respectively.
A consent judgment is a court-entered order reflecting terms agreed by both parties, carrying full judicial enforcement weight. In pharmaceutical patent disputes, it typically encodes negotiated market-entry dates or licensing terms without requiring either party to admit infringement or invalidity. The specific commercial terms usually remain confidential.
The case was filed on 27 June 2023 and closed on 29 February 2024 — a duration of 247 days. This is notably fast for pharmaceutical patent litigation in Delaware, where complex ANDA-related cases frequently proceed to trial over two to four years.
Yes. A consent judgment resolves the dispute only between the named parties — Celgene, BMS, MSN Laboratories, and MSN Pharmaceuticals. Both patents remain fully enforceable against any other party developing or commercialising competing oral cytidine analog formulations in the United States.
Delaware District Court is the most common venue for pharmaceutical patent enforcement in the United States, selected for its experienced patent judiciary, predictable case management, and established procedural familiarity with Hatch-Waxman litigation. BMS and Celgene’s choice of Delaware is consistent with standard innovator enforcement strategy.
PatSnap Eureka searches patents and litigation data to answer instantly.